Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Untangling and Understanding the Implications of Roxadustat's MACE Results from 5/9/19

Ticker(s): FGEN, AZN, AKBA

Who's the expert?

Name: Dr Richard Hellman - MD

Institution: Indiana University

  • Emeritus Associate Professor of Clinical Medicine, Division of Nephrology at Indiana University.
  • Attends on Renal Services 12-18 weeks per year. 
  • Investigator in multiple CKD clinical trials including epoetin alfa and darbepoetin alfa.

Interview Questions

What is your initial reaction to the MACE Analysis release on 5/9/19?

Added By: joe_mccann

Is the annual reduction in eGFR decline versus placebo in NDD (1.62 mL/min/1.73m2 reduction, or 38% reduction vs placebo) clinically meaningful? How does this factor into your risk/benefit analysis for NDD patients?

Added By: joe_mccann

How does the MACE/MACE+ hazard ratio (HR) point estimate versus upper bound of the 95% CI factor into your risk/benefit analysis? For example, do you think roxa will get wide use in NDD if the HR is between 1.0-1.1 but the upper bound of the 95% CI is less than 1.3 (assuming no black box for CV events)?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.